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Drug resistance in Mycobacterium tuberculosis has become a serious global health threat, which is now
complicated by the emergence of extensively drug-resistant strains. New drugs that are active against drug-
resistant tuberculosis (TB) are needed. We chose to search for new inhibitors of the enoyl-acyl carrier protein
(ACP) reductase InhA, the target of the first-line TB drug isoniazid (also known as isonicotinoic acid hydrazide
[INH]). A subset of a chemical library, composed of 300 compounds inhibiting Plasmodium falciparum enoyl
reductase, was tested againstM. tuberculosis. Four compounds were found to inhibitM. tuberculosis growth with
MICs ranging from 1 M to 10 M. Testing of these compounds against M. tuberculosis in vitro revealed that
only two compounds (CD39 and CD117) were bactericidal against drug-susceptible and drug-resistant M.
tuberculosis. These two compounds were also bactericidal against M. tuberculosis incubated under anaerobic
conditions. Furthermore, CD39 and CD117 exhibited increased bactericidal activity when used in combination
with INH or rifampin, but CD39 was shown to be toxic to eukaryotic cells. The compounds inhibit InhA as well
the fatty acid synthase type I, and CD117 was found to also inhibit tuberculostearic acid synthesis. This study
provides the TB drug development community with two chemical scaffolds that are suitable for structure-
activity relationship study to improve on their cytotoxicities and bactericidal activities in vitro and in vivo.
The fight against tuberculosis (TB), a disease caused by the
bacillus Mycobacterium tuberculosis, is facing new challenges
with the surge of multidrug-resistant (MDR) TB and the re-
cent emergence of extensively drug-resistant (XDR) TB (8).
TB strains resistant to the first-line anti-TB drugs (FLDs)
isoniazid (also known as isonicotinoic acid hydrazide [INH])
and rifampin (RIF) are classified as MDR-TB, while XDR-TB
is defined as MDR-TB resistant to any fluoroquinolone and
one or more of the three injectable drugs (6). The need for
novel TB drugs has spurred a new interest in TB drug devel-
opment, and several new TB drugs are currently being tested in
clinical trials (18). Nevertheless, expanding the pharmacopeia
of active TB drugs remains an important goal, as M. tubercu-
losis has proven to be more than adept at acquiring drug
resistance. One strategy to develop new drugs effective against
MDR- and XDR-TB is to target essential functions that are
not aims of the current anti-TB drug regimen. An alternative is
to develop new drugs with novel requirements for inhibition of
a bona fide target, with the goal of circumventing extant drug
resistance.
TB is resistant to most commonly used antibacterial agents
due in part to its unusual cell wall structure. The mycobacterial
cell wall contains unique long-chain (C70 to C90), -alkyl, -hy-
droxy fatty acids called mycolic acids. The synthesis of these
fatty acids requires the coenzyme A (CoA)-dependent fatty
acid synthase type I (FASI) and the acyl carrier protein (ACP)-
dependent multienzyme fatty acid synthase type II (FASII)
systems. FASI produces fatty acids of up to C16 and C26 chain
lengths, and FASII elongates these fatty acids to meromyco-
lates. Condensation of meromycolates with the end product of
FASI produces mycolic acids (4, 37). The FASII enzymes are
viable targets for drug development, since eukaryotic cells use
only a FASI-type enzyme to synthesize fatty acids (10). Two
enzymes of the mycobacterial FASII system are already targets
of antimycobacterial drugs: the -keto-acyl-ACP reductase
KasA, targeted by thiolactomycin (34), and the enoyl-ACP
reductase InhA, which is inhibited by INH (40). INH is a
prodrug that is activated by the catalase-peroxidase KatG (13)
to form an isonicotinoyl radical which reacts with NAD to
produce an INH-NAD adduct (17, 31, 42), which inhibits InhA
(17, 23, 29, 40, 42). A large majority of INH-resistant (INHR)
M. tuberculosis clinical isolates have mutations in the activator
of INH, KatG, not the target of INH, InhA (38). The inhA
gene is essential in mycobacteria, and inhibition of InhA en-
zymatic activity leads to mycobacterial cell death (39). InhA, as
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a drug target, has been validated by several studies (5, 9, 20, 24,
33, 36). GlaxoSmithKline and the TB Alliance have conducted
an InhA target-based screen of a million compounds and are in
the lead optimization phase (http://www.tballiance.org/new
/portfolio/html-portfolio-item.php?id5). Series of analogs of
triclosan, another InhA inhibitor (25), that showed good ac-
tivities against the enoyl reductase InhA of M. tuberculosis (7),
as well as the enoyl reductase PfENR of Plasmodium falcipa-
rum (15), have also been synthesized. Our goal was to identify
new InhA inhibitors that, unlike INH, do not require activation
by KatG and could therefore be active against katG-deficient
INHR M. tuberculosis strains. Therefore, our screening activi-
ties commenced with the extension of a previously conducted
campaign against PfENR (14). Our experience with numerous
chemotypes, including diaryl ether phenols, indoles, and pyra-
zoles, supported the notion that PfENR inhibitors may also
show significant efficacy against InhA. Thus, we examined a
subset of 300 hits (ChemDiv; San Diego, CA) against PfENR,
characterized by40% enzyme inhibition at 10 M compound
and drug-like properties (less than two violations of Lipinski’s
Rule of Five [19]). Herein, we describe the screening and
testing of these compounds against whole cells of M. tubercu-
losis.
MATERIALS AND METHODS
Bacterial strains and media. The M. tuberculosis strains were obtained from
laboratory stocks. The clinical isolates were selected from an anonymized col-
lection of clinical M. tuberculosis isolates. The isolates were derived from clinical
tuberculosis patients in Mexico. 5071 and 5483 are single nucleotide polymor-
phism (SNP) cluster group 3b, while 12081 is SNP cluster group 5, both consis-
tent with the predominant strain types in the Americas. The strains were grown
in Sauton medium (16) supplemented with 0.05% (vol/vol) tyloxapol unless
otherwise indicated. The solid medium used was Middlebrook 7H10 medium
(Difco) supplemented with 10% (vol/vol) ADS enrichment (50 g albumin, 20 g
dextrose, 8.5 g sodium chloride, in 1 liter of water) and 0.2% (vol/vol) glycerol.
The chemical library was obtained from ChemDiv (San Diego, CA). All other
chemicals used in this study were obtained from Sigma (St. Louis, MO) and
ChemBridge (San Diego, CA) or were synthesized utilizing established methods
(3, 11, 30).
MIC determination. Each compound from the chemical library was dissolved
in dimethyl sulfoxide (DMSO) at a concentration of 10 mg/liter. The MICs were
determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay (21). In this assay, the MIC was determined by visual inspection
as the lowest concentration of compound that prevented the conversion of MTT
(yellow solution) to formazan (blue/violet solution). If a compound reacted with
MTT, the MIC determination was then performed in Falcon tubes containing
2-fold serial dilution of the compound in Sauton medium (2 ml), to which was
added the M. tuberculosis strain (104 CFU in 0.1 ml of Sauton). The tubes were
incubated at 37°C for 4 weeks. Compounds were tested at concentrations ranging
from 0.15 mg/liter to 40 mg/liter. In broth dilution assays, the MIC was deter-
mined as the lowest concentration of compound that prevented visible growth.
Determination of anaerobic bactericidal activity of ChemDiv compounds.
Select ChemDiv compounds were tested for bactericidal activity on nongrowing
populations of M. tuberculosis. M. tuberculosis strain mc27000 (H37Rv RD1
panCD) was grown under a normal aerobic atmosphere in 7H9 medium sup-
plemented with ADS, 0.5% glycerol, 0.05% tyloxapol, and 50 mg/liter panto-
thenic acid to an optical density at 600 nm (OD600) of 0.5. Actively growing
cultures were then shifted to a hypoxic glove box (Coy Laboratory Products,
Grass Lake, MI) containing an anaerobic atmosphere (0.0001% O2, 5% CO2,
10% H2, 85% N2), which rapidly arrested growth but did not have a measurable
effect on culture viability. After 48 h of anaerobic incubation, bacilli were inoc-
ulated 1:50 to anaerobic 7H9 (supplemented as described above) containing test
compounds at the indicated concentrations. Viability was assessed over time by
determining CFU per milliliter of culture on 7H10 medium supplemented with
ADS, 0.2% glycerol, and 50 mg/liter pantothenic acid.
Analysis of FAMEs and MAMEs by TLC. M. tuberculosis H37Rv cultures (10
ml), grown in Sauton medium to an OD600 of 	0.35, were treated with selected
ChemDiv compounds for 20 h and then labeled with [1-14C]acetate for 6 h. The
cultures were spun, and the cell pellets were washed once with distilled water,
resuspended in distilled water (1 ml), and added to a 40% solution of tetrabu-
tylammonium hydroxide (1 ml). The suspension was heated at 100°C for 16 h.
After cooling, methyl iodide (0.1 ml) and methylene chloride (2 ml) were added,
and the samples were mixed for 1 h at 20°C. The organic phase was washed with
a 3N aqueous hydrochloric acid solution followed by a wash with distilled water,
drying, and resuspension in methylene chloride (0.2 ml). The fatty acid methyl
esters (FAMEs) and mycolic acid methyl esters (MAMEs) were analyzed by
spotting 5 l of the extract onto a silica gel 60 F254 thin-layer chromatography
(TLC) plate. The TLC plate was eluted three times with hexane-ethyl acetate
(95/5, vol/vol) and the FAMEs and MAMEs were detected by autoradiography
after exposure for 24 to 48 h at 
80°C.
Analysis of fatty acids by HPLC. M. tuberculosis H37Rv cultures (10 ml),
grown in Sauton medium to an OD600 of 0.35, were treated with different
concentrations of CD117 (0, 1, 5, and 10 mg/liter) for 20 h, followed by labeling
with [1-14C]acetate for 6 h. After centrifugation, the cell pellets were washed
once with distilled water (10 ml) and then saponified with a 20% aqueous
solution of tetrabutylammonium hydroxide (1 ml) overnight at 100°C. The fatty
acids were extracted, derivatized to their UV-absorbing p-bromophenacyl esters,
and analyzed on a Hewlett-Packard model HP1100 high-performance liquid
chromatograph (HPLC) coupled to an IN/US -RAM flowthrough radioisotope
beta-gamma radiation detector as described previously (39). Fatty acid standards
were derivatized and analyzed by HPLC similarly, and the resulting chromato-
grams were used to identify the peaks from the experimental chromatograms.
Cytotoxicity assay. African green monkey kidney cells (Vero cells, ATCC,
Manassas VA) were seeded into 96-well plates and cultured with Dulbecco
modified Eagle medium (DMEM) containing 10% fetal bovine serum in the
presence of varying amounts of CD39 (0.39 to 50 mg/liter), CD117 (0.39 to 50
mg/liter), INH (2.5 to 5000 mg/liter), and RIF (0.25 to 500 mg/liter). After
incubation at 37°C for 2 days, cell viability was measured using the MTT assay
(22). Plates were read at 595 nm using a DTX880 plate reader.
Macrophage experiment. Bone marrow-derived macrophages (BMDM) were
prepared from C57BL/6 mice by flushing isolated femurs with Dulbecco modi-
fied Eagle medium (DMEM; Gibco) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 2 mM L-glutamine, and 1 nonessential amino acids
(complete DMEM). The cells were cultured for 7 days, on petri dishes, in
complete DMEM also supplemented with recombinant murine macrophage
colony-stimulating factor (M-CSF; Peprotech) at 20 ng/ml; the cytokine was
replenished once during this 7-day culture period. After 7 days, the cells were
detached using cold phosphate-buffered saline (PBS) with 5 mM EDTA, washed
in complete DMEM, and resuspended in DMEM with M-CSF at 10 ng/ml. The
cells were seeded into 24-well plates (2 105 to 3 105 cells/well) and permitted
to adhere overnight prior to infection. The macrophages were infected with M.
tuberculosis H37Rv that was grown to an OD600 of 	1 in 7H9 medium supple-
mented with oleic acid-albumin-dextrose-catalase (OADC), 0.2% glycerol, and
0.05% Tween 80, washed and resuspended in complete DMEM and diluted to
the appropriate titer in complete DMEM. The bacteria were added to the wells
at an approximate multiplicity of infection (MOI) of 5. Following 4 h of incu-
bation at 37°C to permit bacterial uptake, macrophage monolayers were washed
twice with PBS to remove extracellular bacteria, following which wells were
replenished with complete DMEM containing M-CSF at 10 ng/ml. At this point,
the test compounds were added to the wells. These included CD117, INH, or
RIF, alone or in combination, as well as DMSO as the vehicle control. At various
times after infection, the medium was removed to a tube containing sufficient
SDS to give a final concentration of 0.025%; the cell monolayers were lysed with
0.025% SDS and combined with the medium. The lysates were diluted in PBS
with 0.05% Tween 80 and plated onto 7H10 agar (with 10% OADC, 0.5%
glycerol) for determination of bacterial numbers.
RESULTS
Screening against whole-cell M. tuberculosis. The 300 com-
pounds previously identified as PfENR inhibitors (14) were
tested by spotting 5, 10, 20, and 40 g of each compound on an
M. tuberculosis H37Rv lawn. After incubation of the plates for
3 weeks at 37°C, clearing of the mycobacterial lawn was ob-
served for 64 compounds, which were then tested for inhibition
of M. tuberculosis growth in liquid cultures at a concentration
of 20 mg/liter. Only 11 compounds retarded or inhibited the
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growth of M. tuberculosis at this concentration. Their MICs
were determined, and they ranged between 1 M and 100
M against wild-type (wt) M. tuberculosis (Table 1). The four
compounds with MICs below 10 M (CD13, CD39, CD59, and
CD117) were then investigated further for bactericidal activity.
M. tuberculosis H37Rv was first treated with each compound at
the concentration of 20 mg/liter, and kill curves were per-
formed by measuring CFU for a period of 3 weeks (Fig. 1).
Treatment of M. tuberculosis with CD13 and CD59 resulted in
no more than a 2-log decrease in CFU titers after 3 weeks. By
contrast, treatment of M. tuberculosis with CD117 and CD39
was a bactericidal event with up to a 4-log decrease in CFU
titers. To examine if the activity of the compounds was strain
specific, we treated M. tuberculosis Erdman, M. tuberculosis
CDC1551, and M. tuberculosis Beijing with CD39 or CD117 at
20 mg/liter and observed the same reduction in CFU as with M.
tuberculosis H37Rv.
TABLE 1. MIC and chemical structure of active ChemDiv compounds against M. tuberculosis strains
Compound Structure
MIC (M)
Compound Structure
MIC (M)
H37Rv mc24914 H37Rv mc24914
CD13 8.5 33.9 CD117 1 4
CD39 9.0 26.9 CD206 100 ND
CD56 38.5 NDa CD230 20.5 ND
CD59 1.5 3.2 CD231 68.6 ND
CD66 40.4 ND CD233 113 ND
CD69 17.1 ND INH 0.4 6
a ND, not done.
FIG. 1. Growth of M. tuberculosis H37Rv treated with CD13,
CD39, CD59, and CD117 at 20 mg/liter. Cultures, grown in Sauton
medium, were incubated at 37°C, and CFU were determined by plating
10-fold dilutions of each cultures onto Middlebrook 7H10 agar plates.
Each growth curve was done in triplicate, and the averages with stan-
dard deviations are plotted.
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Activity of CD39 and CD117 against drug-resistant M. tu-
berculosis strains. Since our goal was to identify InhA inhibi-
tors that would be active against INHR clinical isolates, where
the main mechanism of INH resistance is mutations in katG
(38), we tested CD39 and CD117 against mc24977, an M.
tuberculosis H37Rv strain that has a base pair deletion (del
g371) in katG resulting in a frameshift mutation and high
resistance to INH (MIC  100 mg/liter). Surprisingly, both
compounds were more active against this INHR M. tuberculosis
strain than they were against wt M. tuberculosis (Fig. 2). Treat-
ment of mc24977 with either CD39 or CD117 resulted in a
6-log decrease in CFU titers after 14 days. To assess if this
increased activity against the INHR M. tuberculosis strain was a
general phenomenon or existed only in a katG mutant, we
tested three clinical isolates with different drug resistance pat-
terns: CI5071, resistant to INH and streptomycin; CI5483,
which is ethambutol and streptomycin resistant; and CI12081,
resistant to INH, RIF, and streptomycin. Again, we observed a
better inhibition of the drug-resistant (DR) TB strains than of
wt M. tuberculosis (Fig. 2). This increase in bactericidal activity
was not observed for CD13 and CD59. These two compounds
showed the same level of killing for wt M. tuberculosis and for
DR-TB strains.
Activity of CD39 and CD117 in combination with FLDs.
Since monotherapy is not an accepted protocol for treatment
of TB, the interactions of the compounds CD39 or CD117 with
current FLDs were tested to determine if the compounds could
be used in combination with FLDs. We tested a combination of
CD39 or CD117 (10 mg/liter) with INH at a concentration of
0.2 mg/liter (4MIC). After 3 weeks of treatment, a reduction
of more than 6 logs of CFU/ml was observed when M. tuber-
culosis H37Rv was treated with INH and CD39 or CD117 (Fig.
3A). By contrast, the culture of M. tuberculosis treated with
CD39 alone had almost the same titer as the untreated culture,
while treatment of M. tuberculosis with INH or CD117 resulted
in a 2-log decrease in CFU after 3 weeks (Fig. 3A). Similar
killing was also obtained when the concentration of CD39 or
CD117 was decreased to 1 mg/liter in combination with 0.2
mg/liter of INH (data not shown). The addition of INH to the
compounds was essential to the increased activity, since de-
creasing the amount of INH by half resulted in reduced killing
(Fig. 3B). When used in combination with a low concentration
of RIF (0.25 mg/liter), a limited effect was observed with CD39
(1-log increase in killing), while the combination of CD117 and
RIF resulted in a 4-log increase in killing compared to CD117
alone (Fig. 3B).
Activity of CD39 and CD117 under anaerobic conditions.
Another challenge faced by TB eradication programs is the
ability of M. tuberculosis to enter latency and persist in an
infected person for many years or decades. To fully eradicate
TB, new drugs will have to be able to kill these persistent
populations of bacilli. As the hypoxic lumen of the granuloma
is predicted to be a site of residence for dormant persistent
bacilli, a common in vitro model for M. tuberculosis dormancy
is the Wayne model (41), where mycobacterial cultures are
subjected to a gradual loss of oxygen that likely mimics the
FIG. 2. Treatment of drug-resistant M. tuberculosis strains with INH (1 mg/liter), CD39 (20 mg/liter), and CD117 (20 mg/liter) in Sauton
medium. mc24977 is an INH-resistant laboratory strain containing a single base pair deletion in katG. The three clinical isolates CI5483, CI5071,
and CI12081 are resistant to ethambutol and streptomycin, INH and streptomycin, and INH, RIF, and streptomycin, respectively. The cultures
were incubated with shaking at 37°C, and CFU were determined by plating 10-fold serial dilutions onto Middlebrook 7H10 plates. Each experiment
was done in duplicate, and the averages are plotted with standard deviations.
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hypoxic conditions inside granulomas. To test if CD39 and
CD117 were active against nongrowing hypoxic bacilli, M. tu-
berculosis was grown under aerobic conditions to early log
phase and then shifted to anaerobic conditions inside an an-
aerobic chamber. Once the bacilli were adapted to this condi-
tion, they were subcultured to anaerobic medium containing
different concentrations of CD39 or CD117, and CFU titers
were determined over time (Fig. 4). The effects of CD39 and
CD117 were found to be concentration dependent. In contrast
to what was observed for aerobic treatment, CD117 showed
limited activity for the first 2 weeks of anaerobic treatment
(Fig. 4A). However, this period of anaerobic tolerance was
followed by a rapid concentration-dependent decrease in cul-
ture viability. Conversely, treatment of hypoxic bacilli with high
concentrations of CD39 (10 and 20 mg/liter) resulted in a rapid
acute decrease in CFU titers. Yet, after 6 days of treatment,
continued bactericidal activity was observed only at the highest
concentration (20 mg/liter) that was tested. In comparison,
INH at 1 mg/liter has no activity against M. tuberculosis incu-
bated under hypoxic conditions, while RIF at 1 mg/liter main-
tained bactericidal activity, resulting in a 3-log killing of M.
tuberculosis in 21 days (data not shown).
Activity of CD39 and CD117 on eukaryotic cells. M. tuber-
culosis is an intracellular pathogen. In the early stages of in-
fection, M. tuberculosis is primarily found in alveolar macro-
phages. Therefore, it was necessary to determine the level of
toxicity of the compounds to eukaryotic cells and then assess if
the compounds could kill M. tuberculosis inside a macrophage.
Toxicity data were obtained using African green monkey kid-
ney cells (Vero cells). The highest tolerated dose (HTD) in
FIG. 3. Combination of CD39 and CD117 with FLDs. M. tuberculosis H37Rv, grown in Sauton, was treated with compounds alone or in
combination with INH (A and B) or RIF (B). The cultures were incubated with shaking at 37°C. CFU were determined by plating 10-fold serial
dilutions onto Middlebrook 7H10 plates. Concentrations are given in mg/liter. Each experiment was done in triplicate, and the averages with
standard deviations are plotted.
FIG. 4. Bactericidal activity of CD39 and CD117 on hypoxically
dormant M. tuberculosis. M. tuberculosis mc27000 was grown aerobi-
cally in 7H9 medium supplemented with ADS, 0.5% glycerol, 0.05%
tyloxapol, and 50 mg/liter pantothenic acid. Bacilli were shifted to an
anaerobic atmosphere containing 0.0001% O2, 5% CO2, 10% H2,
and 85% N2. After 48 h, cells were subcultured to anaerobic 7H9
(supplemented as above) containing the indicated concentrations (in
mg/liter) of CD117 (A) and CD39 (B), and colony-forming-units
(CFU) were determined by plating 10-fold dilutions of each culture
onto Middlebrook 7H10 agar plates.
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Vero cells was 3 M for CD39 (0.8 mg/liter). CD117 at the
highest concentration tested (132 M, 50 mg/liter) had a lim-
ited effect (20% cell viability reduction) on the Vero cells. For
comparison, the HTDs for INH and RIF in this assay were 14
mM (1.9 g/liter) and 0.6 mM (0.5 g/liter), respectively. The
ratio between the maximum concentration of drug tolerated by
the mammalian cells and the MIC was 0.3 for CD39 and 132
for CD117, leading us to conclude that CD39 was toxic and
would require chemical modifications for further study. Thus,
only CD117 was tested for killing of M. tuberculosis in a mac-
rophage. Bone marrow-derived macrophages (BMDM) from
C57BL/6 mice were infected with M. tuberculosis H37Rv for
4 h and then washed to remove extracellular bacteria prior to
the addition of CD117 (10 and 20 mg/liter) (Fig. 5A). The
effect of CD117 was dose dependent and resulted in a 1-log
decrease in CFU after 24 h, followed by a continuous small
decrease in CFU at 20 mg/liter. At 10 mg/liter, a small decrease
in CFU was observed for the first 2 days (70%), followed by
stabilization (Fig. 5A). Since the in vitro bactericidal activity
increased when INH or RIF was added to CD117, the combi-
nation of CD117 with low concentrations of INH (0.2 mg/liter)
or RIF (0.25 mg/liter) was also tested in BMDM infected with
H37Rv. Surprisingly, no improvement in the killing of H37Rv
was observed when combining INH and CD117 (Fig. 5B). In
contrast, the combination of RIF and CD117 resulted in 3-
log killing of H37Rv (Fig. 5C). The combined effect of CD117
and RIF was more important than the additional effect of RIF
alone, which had limited killing activity (60% reduction in
CFU), and of CD117 alone (1.5-log killing) after 6 days. A
similar pattern was observed with lower concentrations of
CD117 (5 and 10 mg/liter). Adding INH to CD117 at 5 or 10
mg/liter did not improve killing of M. tuberculosis, while the
addition of RIF (0.25 mg/liter) to CD117 (5 and 10 mg/liter)
resulted in an additional 1-log killing compared to CD117
alone (data not shown).
Mode of action of CD39 and CD117. InhA is the NADH-
dependent enoyl-ACP reductase of the FASII system, involved
in mycolic acid biosynthesis. It was previously shown that in-
hibition of InhA resulted in inhibition of mycolic acid biosyn-
thesis and accumulation of long-chain fatty acids (39). To de-
termine if CD39 and CD117 did in fact target InhA, mycolic
acid biosynthesis in M. tuberculosis treated with CD39 or
CD117 was analyzed by thin-layer chromatography. At 10 mg/
liter, only CD117 had an effect on the biosynthesis of mycolic
acids (MAMEs), while treatment of M. tuberculosis with CD39
resulted in a fatty acid (FAME) and mycolic acid profile sim-
ilar to that of the control (Fig. 6A). When the concentration of
compounds was doubled, inhibition of mycolic acid biosynthe-
sis was observed for M. tuberculosis treated with CD39 and
CD117 (Fig. 6B). Furthermore, inhibition of fatty acid biosyn-
thesis was almost complete for M. tuberculosis treated with
CD117, and a decrease in fatty acid production was also ob-
served in the CD39 treatment.
To further determine whether InhA was the target of CD39
and CD117, the compounds were tested against mc24914, an
M. tuberculosis strain overexpressing InhA (40). Although
FIG. 5. Growth of M. tuberculosis H37Rv, treated with CD117 at 10 or 20 mg/liter (A), INH  CD117 (B), or RIF  CD117 (C), in bone
marrow-derived macrophages (BMDM). Drug treatment was initiated after a 4-h infection period. At each time point, macrophages were lysed, and
10-fold serial dilutions were plated on Middlebrook 7H10 plates to determine CFU counts. Concentrations are given in mg/liter. Each experiment was
done in triplicate, and the averages with standard deviations are plotted.
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mc24914 was 3 to 4 times more resistant to the compounds
than wt M. tuberculosis, the level of resistance was weak com-
pared to the resistance of mc24914 to INH (Table 1). For
comparison, mc24914 is 15 times more resistant to INH than is
the wt. The low-level resistance to CD39 and CD117 observed
in mc24914 suggested that, while the compounds do inhibit
InhA, they must also target other enzymes.
During the testing of the compounds against wt M. tubercu-
losis, we examined if the inhibition observed was medium de-
pendent. All the in vitro experiments described above had been
done in Sauton medium supplemented with tyloxapol. Surpris-
ingly, the compounds showed no activity against M. tuberculosis
grown in Middlebrook 7H9 supplemented with oleic
acid-albumin-dextrose-catalase (OADC) but were still as ac-
tive in Middlebrook 7H9 supplemented with albumin-dex-
trose-saline (ADS). Antimycobacterial drugs, such as isoxyl,
are known to inhibit oleic acid biosynthesis. To examine if there
was a correlation between the mode of action of the compounds
and oleic acid biosynthesis, fatty acids produced by M. tuberculosis
when treated with increasing concentrations of CD117 were an-
alyzed by high-performance liquid chromatography (HPLC). No
decrease in oleic acid biosynthesis was observed when M. tuber-
culosis was treated with 1, 5, or 10 mg/liter of CD117, but a
reduction in tuberculostearic acid (TA) was found (Fig. 7A).
Analysis of the fatty acid distribution showed that the loss of
tuberculostearic acid was dependent on the concentrations of
CD117 used (Fig. 7B). Interestingly, an accumulation of long-
chain fatty acids was also observed with increased concentrations
of CD117, an event known to occur when InhA and subsequently
the FASII system are inhibited (39).
To find out which other gene or genes were targeted by
CD117, the isolation of CD117-resistant mutants was at-
tempted in two independent experiments. M. tuberculosis
H37Rv (109 cells) was plated on Middlebrook 7H10 plates
supplemented with ADS and containing CD117 at 10 and 20
times the MIC. The plates were incubated for 5 to 6 weeks at
37°C. No CD117-resistant mutants could be obtained.
Chemical structure versus antimycobacterial activity. To
assess which part of the CD117 molecule was important for the
antimycobacterial activity, analogs of CD117 were tested
against M. tuberculosis H37Rv. CD117 has two major structural
components: the tetrahydrobenzothienopyrimidine and the
ethyl 2-thioacetate chain (Table 2). The thioacetate group was
FIG. 6. Analysis of fatty acid (FAMEs) and mycolic acid (MAMEs)
biosynthesis by thin-layer chromatography (TLC). M. tuberculosis
H37Rv, grown in Sauton medium, was treated with CD39 or CD117 at
either 10 mg/liter (A) or 20 mg/liter (B) for 20 h and then labeled with
[1-14C]acetate for 6 h. Fatty acids were saponified, extracted, and
derivatized (see Materials and Methods). Equal amounts of extracted
fatty acids were spotted on TLC. The TLC was run three times in
hexane-ethyl acetate (95/5, vol/vol), and fatty acids were detected by
autoradiography. The control is untreated M. tuberculosis.
FIG. 7. Analysis of fatty acid production by high-performance liquid chromatography (HPLC). M. tuberculosis H37Rv was treated with 0, 1, 5,
or 10 mg/liter of CD117 for 20 h and then labeled with [1-14C]acetate for 6 h. Fatty acids were saponified, extracted, and derivatized (see Materials
and Methods) prior to HPLC analysis. (A) HPLC chromatograms. The peaks were identified by comparison with known standards. Labels are as
follows: 16:0, palmitic acid; 18:1, oleic acid; 18:0, stearic acid; TA, tuberculostearic acid; 20:0, eicosanoic acid; 24:0, tetracosanoic acid; 26:0,
hexacosanoic acid. (B) Percentage of fatty acid (FA) in each experiment as determined by the chromatograms’ peak intensity reports.
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modified by replacing the ethyl ester with a methyl ester (an-
alog CD117a), an amide (CD117e), or an alcohol (CD117f) or
removing the ethyl ester (CD117d). At the other end of the
molecule, the t-butyl group was excised (analog CD117b).
Regarding the tricyclic heterocycle (comprised of pyrimi-
dine, thiophene, and cyclohexene elements), the pyrimidine
ring was opened (analog CD117c). Only CD117a retained
antimycobacterial activity (Table 2). From this limited set of
CD117 analogs, we can conclude that one essential chemical
group in CD117 is the thioacetate, since replacing the car-
boxylic group by an alcohol or removing it resulted in total
loss of the antimycobacterial activity. Furthermore, chang-
ing the ester into an amide group led to a severe reduction
in activity, lending support to the idea that the ester moiety
may serve as a prodrug for the carboxylic acid. Another
important group is the t-butyl group attached to the cyclo-
hexene ring, since its removal resulted in a decrease of the
antimycobacterial activity. The fact that such small changes
in the chemical structure of CD117 affected its antimyco-
bacterial activity argues against the possibility that the com-
pound’s activity is nonspecific.
DISCUSSION
Drug resistance in M. tuberculosis has become a major health
problem, and the WHO estimates that worldwide up to 28% of
the TB cases are INHR and that, in previously treated TB
cases, the level of INH resistance can reach 60%. The main
target of INH is the enoyl reductase InhA, yet the main mech-
anism of INH resistance in TB clinical isolates is mutations in
the activator of INH, KatG. In order to identify new inhibitors
of InhA that did not require KatG activation, we tested a
subset (300 compounds) of a chemical library, composed of
inhibitors of the P. falciparum enoyl-reductase PfENR, against
whole-cell M. tuberculosis. Although the enoyl reductases of M.
tuberculosis and P. falciparum have limited similarities at the
protein level (28% identical, 44% similar), two compounds,
CD39 and CD117, were found to have bactericidal activity
against drug-susceptible M. tuberculosis under both aerobic
and anaerobic conditions. More importantly, both compounds
were also bactericidal against DR- and MDR-TB. Treatment
of MDR-TB with one dose of CD39 and CD117 resulted in the
near sterilization of the cultures. This sterilization effect might
reflect the lack of fitness of MDR-TB strains, since the com-
pounds were in fact much more active against MDR-TB than
against wt M. tuberculosis.
The novel TB drugs currently in clinical trials were not
discovered through target-based cell screening but through
either whole-cell phenotypic screening (TMC207 [1]) or chem-
ical modification of previous hits (PA-824 [35], SQ109 [12],
and OPC-67683 [28]). The advantage of target-based chemical
library screening is that the target of the identified inhibitors is
known, which means that the mode of action and mode of
resistance can be easily identified. In this study, although the
initial enzymatic screen was done to identify inhibitors of
PfENR, the whole-cell screening of M. tuberculosis led to the
identification of CD39 and CD117 that, indeed, did target the
M. tuberculosis enoyl-reductase InhA, as shown by biochemis-
try (inhibition of mycolic acid biosynthesis) and genetics (MICs
increased 4-fold for an M. tuberculosis strain overexpressing
inhA). Nonetheless, their inhibitory activity was not limited to
this enzyme. Treatment of M. tuberculosis with these com-
pounds resulted in the inhibition of mycolic acid and long-
chain fatty acid biosyntheses, indicating that the compounds
inhibit both fatty acid synthases types I and II. Furthermore,
CD117 has also been shown to inhibit tuberculostearic acid
biosynthesis. This combination of phenotypes is reminiscent of
isoxyl, a drug used in the 1960s for the treatment of TB. Isoxyl
(1,3-bis[4-(3-methylbutoxy)phenyl]thiourea) inhibits the bio-
synthesis of mycolic acids (43), short-chain fatty acids (26),
oleic acid, and subsequently tuberculostearic acid (27). Isoxyl
targets the 9-desaturase DesA3, resulting in the inhibition of
oleic acid biosynthesis (27), but the targets involved in mycolic
and fatty acid biosyntheses are still unknown. One of the ad-
vantages of antibacterials having multiple targets is the re-
duced development of drug resistance (32). For drugs having a
single target, like RIF, a single point mutation in one gene
(rpoB) renders the strain resistant and the drug useless. The
same is true for INH, although here it is the gene involved in
TABLE 2. CD117 chemical modifications’ effect on
antimycobacterial activity
Compound Structure MIC (M)against H37Rv
CD117 1
CD117a 1
CD117b 5
CD117c 31
CD117d 160
CD117e 36
CD117f 160
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the activation of the drug that leads to resistance. The fre-
quency of mutation with CD117 was extremely low (10
9),
which illustrates the fact that CD117 targets multiple enzymes.
The benefits of antibiotic polypharmacology have been well
described in the past, and compounds like CD117 and certainly
isoxyl should certainly be developed or rediscovered in order
to fight the rise of drug resistance in M. tuberculosis clinical
strains.
A search in PubChem (pubchem.ncbi.nlm.nih.gov) revealed
that CD117 had been previously tested in one high-throughput
screen (HTS), but no bioassay result was reported for CD39.
CD117 was found inactive in an HTS for protein interaction
modulators targeting the tyrosine 3-mono-oxygenase/trypto-
phan 5-mono-oxygenase activation protein in Homo sapiens.
Interestingly, 2 analogs of CD117 (CD117e and the methyl
ester of CD117b) were found active in an HTS for new inhib-
itors of Mycobacterium tuberculosis H37Rv performed by the
Southern Research Institute in Birmingham, Alabama. In gen-
eral, a search for all tetrahydrobenzothienopyrimidines in this
data set and all other publicly accessible TB data available
from Collaborative Drug Discovery, Inc. demonstrated that,
indeed, this compound family displays activity against M. tu-
berculosis where most notably substitution on the 2 and 4
positions of the pyrimidine ring drives the structure-activity
relationships (SARs). This observation coupled with our pre-
liminary investigations into the SARs of CD117 argues against
the possibility that the small molecule’s whole-cell activity is
nonspecific. Both CD39 and CD117 are candidates for struc-
ture-activity relationship study to improve activity, decrease
toxicity, and increase solubility (CD39 and CD117 have parti-
tion coefficient [log P] values of 3.97 and 1.33, respectively).
CD39 features an ortho-nitrofuran linked to an iminothiazo-
lidinone via a three-carbon unsaturated spacer. Modifying the
nitro substituent, the 2-furyl moiety, or the connecting three-
carbon spacer (chain length and degree of unsaturation) could
lead to a less toxic compound with reasonable antimycobacte-
rial activity. PA-824 and OPC-67683 were actually discovered
by chemical modification of an initial hit, CGI-17341, a bicyclic
5-nitroimidazole derivative with decent activity against M. tu-
berculosis in vitro and in vivo but high mutagenic properties (2).
The sterilizing activities of CD117 and CD39 against MDR-TB
illustrate the potential of the chemical skeletons of these two
molecules for further drug development, especially against
MDR-TB.
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